Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody-Drug Conjugate in Preclinical Osteosarcoma Models

ABSTRACT: Due to the paucity of validated cell surface osteosarcoma-specific targets, patients with this condition have long been excluded from the benefits of antibody-drug conjugate (ADC) therapy observed in several solid and hematologic malignancies. Our comprehensive surfaceome and RNA-seq profiling approach identified osteosarcoma-specific cell-surface antigens that are highly expressed in osteosarcomas but minimally expressed in normal tissues. As a result, one such antigen, CADM1, was selected for the generation of an ADC.

ORGANISM(S): Homo sapiens

PROVIDER: GSE309827 | GEO | 2026/02/25

REPOSITORIES: GEO